France's Curium Pharma, HIG Capital among bidders for Cardinal Health unit - report
dragana991/iStock via Getty Images
- French medical imaging supplier Curium Pharma and private equity firm HIG Capital are among potential buyers for Cardinal Health's nuclear medicine business.
- The two firms have been shortlisting in bidding for the unit, with final offers due by mid-May, according to a Bloomberg report, which cited people familiar. The business may fetch about $2 billion in a sale.
- The news come after Bloomberg reported late last month that Cardinal Health (NYSE:CAH) was looking at a possible sale of its nuclear medicine business.
- The potential sale also follows after Cardinal Health (CAH) in September entered into a cooperation agreement with activist Elliott Management, which included a business review.
- Cardinal Health (CAH) is set to report Q3 results on Thursday.